About Fable Corp GmbH
As FABLE Corp., we are a multidisciplinary team dedicated on overcoming bottlenecks in Biotechnology with our disruptive approaches and know-how. Since 2014, we develop novel Artificial Intelligence, InfoTech and Engineering Physics solutions; and apply it into Biotech Industry.
This approach allowed us to establish the First A.I.-BioNet and Bio-Blockchain Infrastructure to be applied in Biomedical, Biosecurity, Agriculture, Livestock, Biopharma and to implement DigiTech and many other Industries into Biotech creating new markets.
We came along to transform these unnatural problems in Biotechnology to new opportunities by our disruptive approach to connect Nature into DigiTech.
As FABLE, We Understand the Nature...
The AI Bio-Net is a global network of universal mobile devices (AP-23) developed by Engineering Physics and Artificial Intelligence which results in-place and online detection of biomolecules & viruses with a continuous screening just in seconds and eliminates biological kit & specialized personnel requirements in Biotech Industry.
This Technology solves one of the main bottlenecks of Biotechnology – Indirectness & Digitalization leading the First Bio-Blockchain infrastructure as well.
A.I. Bionet is already empowered by Distributed Cloud Computing, Cyber Security. Blockchain & Cryptocurrency integration is on progress.
Proof-of-Concept of AP-23 is completed by In-Vitro Pre-Clinical & Clinical Trials. Below you can find the key characteristics of the platfrom.
AI-BioNET Key Characteristics
The A.I.-BioNet as a biomedical detection network independent from kits and specialized personnel makes possible to share any new detection algorithm and method in a worldwide network in seconds. This means that when a new biomarker detected by a device connected to A.I.-BioNet the detection capability spreads all around the network simultaneously. In result, both A.I. BioNet itself and also the devices connected are updated continuously and expand their detection capabilities in every update.
All Digital Global BioNetwork
Globalization in seconds: The A.I.-BioNet as a biomedical detection network, independent from kits and specialized personnel makes possible to share any new detection algorithm and method in a worldwide network in seconds. This means that when a new biomarker detected by a device connected to A.I.-BioNet the detection capability spreads all around the network simultaneously.
No Kit Use & Multiple Testing
One for all: The A.I.-BioNet eliminates biochemical additives (kits) and specialized personnel. One of the most unique parts of the A.I. Bionet is to be able to make numerous measurements at once from the same body fluid sample in regard to its independence from the obligation to use biochemical additives.
Results in Seconds
The power of global A.I. Bionet makes it possible to make multiple measurement without the necessity of biochemical kits only in seconds.
The A.I.-BioNet eliminates biochemical additives (kits) and specialized personnel. In result, this technology becomes available for everyone and the cost per measurement reduces to 2%.
Fable BioBucks Token Ecosystem
The first worldwide biomedical device network utilizes A.I. and also blockchain technology: Considering a transaction number volume of a few million transactions per day at the end of first year and a theoretical transaction number volume capacity of tens of billions of transactions per day, A.I.-BioNet will be also active in blockchain technology.
As FABLE Corp., we are a multidisciplinary team dedicated on overcoming bottlenecks in Biotechnology with our disruptive approaches and know-how. Since 2014, we develop novel Artificial Intelligence, InfoTech and Engineering Physics solutions; and apply them into Biotech Industry.
Deniz Unver, M.Sc.
Co-Founder & Managing Partner
Emre Gunerken, Ph.D.
Co-founder, Managing Partner
Serdar Alpan, Prof., M.D., Ph.D.
Erhan YILMAZ, M.Sc. PMP
CDO, Managing Partner
Galip Aydin, Ph.D.
Fable Corp. invites investors as well as Healthcare and Biomedical Industry licensing companies to contact us for possible collaborations.
As we have been focusing on disruptive projects consisting of several multi-disciplinary fields in science and engineering, we are willing to enlarge our academical collaborations in fields of Bioengineering, Engineering Physics, Artificial Intelligence, Bioprocess centric Mechatronics, and Biopharma centric Engineered Autotrophs.
Feel free to contact us for Business, Scientific Cooperation and Partnering Opportunities.
65 E. India Row, Suite 36G
Boston MA 02110, USA
Ertugrul Gazi, A block No:2,
Atasehir, Istanbul, TR